233 results on '"Amiel, Corinne"'
Search Results
2. Methyl-qPCR: a new method to investigate Epstein–Barr virus infection in post-transplant lymphoproliferative diseases
- Author
-
Borde, Chloé, Quignon, Frédérique, Amiel, Corinne, Gozlan, Joël, Marechal, Vincent, and Brissot, Eolia
- Published
- 2022
- Full Text
- View/download PDF
3. Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen.
- Author
-
Raymond, Stéphanie, Nicot, Florence, Pallier, Coralie, Bellecave, Pantxika, Maillard, Anne, Trabaud, Mary, Morand-Joubert, Laurence, Rodallec, Audrey, Amiel, Corinne, Mourez, Thomas, Bocket, Laurence, Beby-Defaux, Agnès, Bouvier-Alias, Magali, Lambert-Niclot, Sidonie, Charpentier, Charlotte, Malve, Brice, Mirand, Audrey, Dina, Julia, Le Guillou-Guillemette, Hélène, Marque-Juillet, Stéphanie, Signori-Schmuck, Anne, Barin, Francis, Si-Mohamed, Ali, Avettand Fenoel, Véronique, Roussel, Catherine, Calvez, Vincent, Saune, Karine, Marcelin, Anne, Rodriguez, Christophe, Descamps, Diane, and Izopet, Jacques
- Subjects
Adult ,Drug Resistance ,Viral ,Female ,Genetic Variation ,HIV Infections ,HIV-1 ,Humans ,Male ,Mutation ,Rilpivirine ,Viral Load - Abstract
BACKGROUND: Minority resistant variants of human immunodeficiency virus type 1 (HIV-1) could influence the virological response to treatment based on nonnucleoside reverse transcriptase inhibitors (NNRTIs). Data on minority rilpivirine-resistant variants are scarce. This study used next-generation sequencing (NGS) to identify patients harboring minority resistant variants to nucleos(t)ide reverse transcriptase inhibitors and NNRTIs and to assess their influence on the virological response (VR). METHODS: All the subjects, 541 HIV-1-infected patients started a first-line regimen containing rilpivirine. VR was defined as a HIV-1 RNA load 20% in 29% of samples. We identified 43 (8.8%) and 36 (7.4%) patients who harbored rilpivirine-resistant variants with a 1% sensitivity threshold according to the French National Agency for Research on AIDS and Viral Hepatitis and Stanford algorithms, respectively. The VR was 96.9% at month 12. Detection of minority rilpivirine resistant variants was not associated with virological failure (VF). Multivariate analysis indicated that VF at month 12 was associated with a CD4 count
- Published
- 2018
4. Caution in interpretation of SARS-CoV-2 quantification based on RT-PCR cycle threshold value
- Author
-
Schnuriger, Aurélie, Perrier, Marine, Marinho, Valérie, Michel, Yanne, Saloum, Kenda, Boukli, Narjis, Lambert-Niclot, Sidonie, Amiel, Corinne, Fofana, Djeneba Bocar, Gozlan, Joël, and Morand-Joubert, Laurence
- Published
- 2021
- Full Text
- View/download PDF
5. Pre-emptive rituximab treatment for Epstein–Barr virus reactivation after allogeneic hematopoietic stem cell transplantation is a worthwhile strategy in high-risk recipients: a comparative study for immune recovery and clinical outcomes
- Author
-
Stocker, Nicolas, Labopin, Myriam, Boussen, Inès, Paccoud, Olivier, Bonnin, Agnès, Malard, Florent, Amiel, Corinne, Gozlan, Joël, Battipaglia, Giorgia, Duléry, Rémy, Giannotti, Federica, Ruggeri, Annalisa, Gaugler, Béatrice, Mohty, Mohamad, and Brissot, Eolia
- Published
- 2020
- Full Text
- View/download PDF
6. Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients
- Author
-
Fourati, Slim, Charpentier, Charlotte, Amiel, Corinne, Morand-Joubert, Laurence, Reigadas, Sandrine, Trabaud, Mary-Anne, Delaugerre, Constance, Nicot, Florence, Rodallec, Audrey, Maillard, Anne, Mirand, Audrey, Jeulin, Hélène, Montès, Brigitte, Barin, Francis, Bettinger, Dominique, Le Guillou-Guillemette, Hélène, Vallet, Sophie, Signori-Schmuck, Anne, Descamps, Diane, Calvez, Vincent, Flandre, Philippe, Marcelin, Anne-Genevieve, Lagier, E, Roussel, C, Le Guillou, H, Alloui, C, Bettinger, D, Pallier, C, Fleury, H, Reigadas, S, Bellecave, P, Recordon-Pinson, P, Payan, C, Vallet, S, Vabret, A, Henquell, C, Mirand, A, Bouvier-Alias, M, de Rougemont, A, Dos Santos, G, Morand, P, Signori-Schmuck, A, Bocket, L, Rogez, S, Andre, P, Tardy, JC, Trabaud, MA, Tamalet, C, Delamare, C, Montes, B, Schvoerer, E, Ferre, V, André-Garnier, E, Cottalorda, J, Guinard, J, Guiguon, A, Descamps, D, Brun-Vézinet, F, Charpentier, C, Visseaux, B, Peytavin, G, Krivine, A, Si-Mohamed, A, Avettand-Fenoel, V, Marcelin, AG, Calvez, V, Lambert-Niclot, S, Soulié, C, Wirden, M, Morand-Joubert, L, Delaugerre, C, Chaix, ML, Amiel, C, Schneider, V, Giraudeau, G, Brodard, V, Maillard, A, Plantier, JC, Chaplain, C, Bourlet, T, Fafi-Kremer, S, Stoll-Keller, F, Schmitt, MP, Barth, H, Yerly, S, Poggi, C, Izopet, J, Raymond, S, Barin, F, Chaillon, A, Marque-Juillet, S, Roque-Afonso, AM, Haïm-Boukobza, S, Flandre, P, Grudé, M, Assoumou, L, Costagliola, D, Allegre, T, Schmit, JL, and Chennebault, JM
- Subjects
Medical Microbiology ,Biomedical and Clinical Sciences ,Infectious Diseases ,Genetics ,Aetiology ,2.1 Biological and endogenous factors ,Infection ,Adult ,Anti-HIV Agents ,Drug Resistance ,Viral ,Female ,France ,HIV Infections ,HIV Integrase ,HIV Protease ,HIV Reverse Transcriptase ,HIV-1 ,Heterocyclic Compounds ,3-Ring ,Humans ,Male ,Middle Aged ,Mutant Proteins ,Oxazines ,Piperazines ,Pyridones ,Quinolones ,Raltegravir Potassium ,Sequence Analysis ,DNA ,integrase ,inhibitors ,mutations ,patterns ,ANRS AC11 Resistance Study Group ,Microbiology ,Pharmacology and Pharmaceutical Sciences ,Clinical sciences ,Pharmacology and pharmaceutical sciences - Abstract
ObjectivesThe objectives of this study were to determine the prevalence and patterns of resistance to integrase strand transfer inhibitors (INSTIs) in patients experiencing virological failure on raltegravir-based ART and the impact on susceptibility to INSTIs (raltegravir, elvitegravir and dolutegravir).Patients and methodsData were collected from 502 treatment-experienced patients failing a raltegravir-containing regimen in a multicentre study. Reverse transcriptase, protease and integrase were sequenced at failure for each patient. INSTI resistance-associated mutations investigated were those included in the last ANRS genotypic algorithm (v23).ResultsAmong the 502 patients, at failure, median baseline HIV-1 RNA (viral load) was 2.9 log10 copies/mL. Patients had been previously exposed to a median of five NRTIs, one NNRTI and three PIs. Seventy-one percent harboured HIV-1 subtype B and the most frequent non-B subtype was CRF02_AG (13.3%). The most frequent mutations observed were N155H/S (19.1%), Q148G/H/K/R (15.4%) and Y143C/G/H/R/S (6.7%). At failure, viruses were considered as fully susceptible to all INSTIs in 61.0% of cases, whilst 38.6% were considered as resistant to raltegravir, 34.9% to elvitegravir and 13.9% to dolutegravir. In the case of resistance to raltegravir, viruses were considered as susceptible to elvitegravir in 11% and to dolutegravir in 64% of cases. High HIV-1 viral load at failure (P
- Published
- 2015
7. Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen
- Author
-
French National Agency for Research on AIDS and Viral Hepatitis (ANRS) AC11 Resistance Study Group, Raymond, Stéphanie, Nicot, Florence, Pallier, Coralie, Bellecave, Pantxika, Maillard, Anne, Trabaud, Mary Anne, Morand-Joubert, Laurence, Rodallec, Audrey, Amiel, Corinne, Mourez, Thomas, Bocket, Laurence, Beby-Defaux, Agnès, Bouvier-Alias, Magali, Lambert-Niclot, Sidonie, Charpentier, Charlotte, Malve, Brice, Mirand, Audrey, Dina, Julia, Le Guillou-Guillemette, Hélène, Marque-Juillet, Stéphanie, Signori-Schmuck, Anne, Barin, Francis, Si-Mohamed, Ali, Fenoel, Véronique Avettand, Roussel, Catherine, Calvez, Vincent, Saune, Karine, Marcelin, Anne Geneviève, Rodriguez, Christophe, Descamps, Diane, and Izopet, Jacques
- Published
- 2018
8. Shared HCV Transmission Networks Among HIV-1–Positive and HIV-1–Negative Men Having Sex With Men by Ultradeep Sequencing
- Author
-
Nguyen, Thuy, Delaugerre, Constance, Valantin, Marc-Antoine, Amiel, Corinne, Netzer, Emmanuelle, Lʼyavanc, Thomas, Ohayon, Michel, Valin, Nadia, Day, Nesrine, Kreplak, Georges, Pialoux, Gilles, Calvez, Vincent, Molina, Jean-Michel, Marcelin, Anne-Geneviève, and Todesco, Eve
- Published
- 2019
- Full Text
- View/download PDF
9. Le virus Epstein-Barr (EBV) : physiopathogenèse et diagnostic
- Author
-
Amiel, Corinne
- Published
- 2013
- Full Text
- View/download PDF
10. A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure
- Author
-
Marcelin, Anne-Geneviève, Delaugerre, Constance, Beaudoux, Céline, Descamps, Diane, Morand-Joubert, Laurence, Amiel, Corinne, Schneider, Veronique, Ferre, Virginie, Izopet, Jacques, Si-Mohamed, Ali, Maillard, Anne, Henquell, Cécile, Desbois, Delphine, Lazrek, Mouna, Signori-Schmuck, Anne, Rogez, Sylvie, Yerly, Sabine, Trabaud, Mary-Anne, Plantier, Jean-Christophe, Fourati, Slim, Houssaini, Allal, Masquelier, Bernard, Calvez, Vincent, and Flandre, Philippe
- Published
- 2013
- Full Text
- View/download PDF
11. CD8 Encephalitis in HIV-Infected Patients Receiving cART: A Treatable Entity
- Author
-
Lescure, François-Xavier, Moulignier, Antoine, Savatovsky, Julien, Amiel, Corinne, Carcelain, Guislaine, Molina, Jean-Michel, Gallien, Sébastien, Pacanovski, Jérôme, Pialoux, Gilles, Adle-Biassette, Homa, and Gray, Françoise
- Published
- 2013
- Full Text
- View/download PDF
12. Additional file 1 of Methyl-qPCR: a new method to investigate Epstein���Barr virus infection in post-transplant lymphoproliferative diseases
- Author
-
Borde, Chlo��, Quignon, Fr��d��rique, Amiel, Corinne, Gozlan, Jo��l, Marechal, Vincent, and Brissot, Eolia
- Abstract
Additional file 1: Figure S1.
- Published
- 2022
- Full Text
- View/download PDF
13. Changes in Blood B Cell Phenotypes and Epstein-Barr Virus Load in Chronically Human Immunodeficiency Virus—Infected Patients before and after Antiretroviral Therapy
- Author
-
Richard, Yolande, Amiel, Corinne, Jeantils, Vincent, Mestivier, Denis, Portier, Alain, Dhello, Guy, Feuillard, Jean, Creidy, Rita, Nicolas, Jean-Claude, and Raphael, Martine
- Published
- 2010
14. Discordance Between Cerebral Spinal Fluid and Plasma HIV Replication in Patients with Neurological Symptoms Who Are Receiving Suppressive Antiretroviral Therapy
- Author
-
Canestri, Ana, Lescure, François-Xavier, Jaureguiberry, Stephane, Moulignier, Antoine, Amiel, Corinne, Marcelin, Anne Geneviève, Peytavin, Gilles, Tubiana, Roland, Pialoux, Gilles, and Katlama, Christine
- Published
- 2010
15. Strong Correlations of Anti–Viral Capsid Antigen Antibody Levels in First-Degree Relatives from Families with Epstein-Barr Virus–Related Lymphomas
- Author
-
Besson, Caroline, Amiel, Corinne, Le-Pendeven, Catherine, Plancoulaine, Sabine, Bonnardel, Colette, Ranque, Brigitte, Abbed, Karim, Brice, Pauline, Fermé, Christophe, Carde, Patrice, Hermine, Olivier, Raphael, Martine, Bresson, Jean-Louis, Nicolas, Jean-Claude, Gessain, Antoine, deThe, Guy, and Abel, Laurent
- Published
- 2009
- Full Text
- View/download PDF
16. Drug resistance and tropism as markers of the dynamics of HIV-1 DNA quasispecies in blood cells of heavily pretreated patients who achieved sustained virological suppression
- Author
-
Gantner, Pierre, Morand-Joubert, Laurence, Sueur, Charlotte, Raffi, François, Fagard, Catherine, Lascoux-Combe, Caroline, Salmon, Dominique, Amiel, Corinne, Lambert-Niclot, Sidonie, Fofana, Djeneba Bocar, Viard, Jean-Paul, Fafi-Kremer, Samira, Rouzioux, Christine, Avettand-Fenoel, Véronique, and Ghosn, Jade
- Published
- 2016
- Full Text
- View/download PDF
17. Virus de la grippe et barrière d’espèce
- Author
-
Amiel, Corinne
- Published
- 2010
- Full Text
- View/download PDF
18. Low level of baseline resistance in recently HCV-infected men who have sex with men with high-risk behaviours
- Author
-
Nguyen, Thuy, Valantin, Marc-Antoine, Delaugerre, Constance, Amiel, Corinne, Netzer, Emmanuelle, L’Yavanc, Thomas, Ohayon, Michel, Valin, Nadia, Day, Nesrine, Kreplak, Georges, Pialoux, Gilles, Calvez, Vincent, Molina, Jean-Michel, Marcelin, Anne-Geneviève, and Todesco, Eve
- Published
- 2021
- Full Text
- View/download PDF
19. Virological failure of patients on maraviroc-based antiretroviral therapy
- Author
-
Raymond, Stéphanie, Maillard, Anne, Amiel, Corinne, Peytavin, Gilles, Trabaud, Mary Anne, Desbois, Delphine, Bellecave, Pantxika, Delaugerre, Constance, Soulie, Cathia, Marcelin, Anne Geneviève, Descamps, Diane, Izopet, Jacques, Reigadas, S., Bellecave, P., Pinson-Recordon, P., Fleury, H., Masquelier, B., Signori-Schmuck, A., Morand, P., Bocket, L., Mouna, L., André, P., Tardy, J. C., Trabaud, M. A., Descamps, D., Charpentier, C., Peytavin, G., Brun-Vézinet, F., Haim-Boukobza, S., Roques, A. M., Soulié, C., Lambert-Niclot, S., Malet, I., Wirden, M., Fourati, S., Marcelin, A. G., Calvez, V., Flandre, P., Assoumou, L., Costagliola, D., Morand-Joubert, L., Delaugerre, C., Schneider, V., Amiel, C., Giraudeau, G., Maillard, A., Nicot, F., and Izopet, J.
- Published
- 2015
- Full Text
- View/download PDF
20. Interleukin-16 (IL-16) Inhibits Human Immunodeficiency Virus Replication in Cells from Infected Subjects, and Serum IL-16 Levels Drop with Disease Progression
- Author
-
Amiel, Corinne, Darcissac, Edith, Truong, Marie-José, Dewulf, Joelle, Loyens, Marc, Mouton, Yves, Capron, André, and Bahr, George M.
- Published
- 1999
21. Initiation of rilpivirine, tenofovir and emtricitabine (RPV/TDF/FTC) regimen in 363 patients with virological vigilance assessment in ‘real life’
- Author
-
Amiel, Corinne, Schneider, Veronique, Guessant, Sabine, Hamidi, Mohammed, Kherallah, Khadijah, Lebrette, Marie-Gisele, Chas, Julie, Lependeven, Catherine, and Pialoux, Gilles
- Published
- 2014
- Full Text
- View/download PDF
22. New Kaposi's sarcoma-associated herpesvirus variant in men who have sex with men 3 associated with severe pathologies Running title: New KSHV variant identified in MSM
- Author
-
Jary, Aude, Leducq, Valentin, Désiré, Nathalie, Petit, Héloïse, Palich, Romain, Joly, Véronique, Canestri, Ana, Gothland, Adélie, Lambert-Niclot, Sidonie, Surgers, Laure, Amiel, Corinne, Descamps, Diane, Spano, Jean-Philippe, Katlama, Christine, Calvez, Vincent, Marcelin, Anne-Geneviève, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Services de Maladies Infectieuses et Tropicales [CHU Bichat], AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service des maladies infectieuses et tropicales [CHU Tenon], CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Services des Maladies Infectieuses et Tropicales [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de virologie [Hôpital Tenon], Service de Virologie [CHU Bichat], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'Oncologie médicale [CHU Pitié-Salpêtrière], and CHU Pitié-Salpêtrière [AP-HP]
- Subjects
ORF-K1 ,whole-genome sequencing ,viruses ,phylogenetic analysis ,virus diseases ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,KSHV ,MSM ,new variant - Abstract
International audience; BackgroundKaposi sarcoma (KS)–associated herpesvirus (KSHV) subtype depends mostly on patient origin. The current study aimed to assess KSHV diversity in a population of men who have sex with men (MSM) living in France.MethodsThe study included 264 patients. In 65 MSM, including 57 human immunodeficiency virus (HIV)–infected men with KS, multicentric Castleman disease, or primary effusion lymphoma and 8 HIV-uninfected men receiving HIV preexposure prophylaxis (PrEP), we performed KSHV typing with K1 open reading frame Sanger and KSHV whole-genome sequencing. In 199 other patients, we performed real-time polymerase chain reaction screening for the new variant.ResultsWe found that 51% of KSHV-strains were subtype C (85% C3), and 33% were subtype A. Four patients with severe KSHV disease (2 with visceral KS, 1 with multicentric Castleman disease, and 1 with primary effusion lymphoma) and 1 asymptomatic PrEP user had a new variant resembling the Ugandan subtype F, but with different K1 open reading frame and KSHV whole-genome sequences and a different epidemiological context (MSM vs African population). Its prevalence was 4.5% in Caucasian MSM, and it was absent in other epidemiological groups.ConclusionsSubtype C predominated among MSM living in France. The new F variant was identified in Caucasian MSM and associated with severe KSHV disease, suggesting that subtype F could be split into F1 and F2 variants. Careful screening for this variant may be required in MSM, given the severe clinical presentation of associated diseases.
- Published
- 2020
23. Surveillance of HIV-1 primary infections in France from 2014 to 2016: toward stable resistance, but higher diversity, clustering and virulence?
- Author
-
Visseaux, Benoit, Assoumou, Lambert, Grude, Maxime, Carles, Marie-Josée, Meyer, Laurence, Roussel, Catherine, Le Guillou-Guillemette, H., Ducancelle, A., Courdavault, L, Alloui, C, Honore, P, Lepiller, Q., Bettinger, D., Bellecave, P., Pinson-Recordon, P, Tumiotto, Camille, Vallet, Sophie, Payan, C., Duthe, J, Leroux, M., Dina, Julia, Vabret, A., Mirand, A., Henquell, C., Bouvier-Alias, Magali, Simohamed, A, dos Santos, G, yerly, S, Gaille, C, Caveng, W, Chapalay, S, Calmy, A., Signori-Schmuck, Anne, Morand, Patrice, Pallier, Coralie, Raho-Moussa, M, Mole, M, Dulucq, M-J, Bocket, Laurence, Alidjinou, K, Ranger-Rogez, S, Trabaud, Mary-Anne, Icard, V, Tardy, J., Tamalet, C., Delamare, C, Montes, Brigitte, Schvoerer, E., Fenaux, H., Rodallec, A., André-Garnier, E., Ferre, Virginie, de Monte, Anne, Guigon, A., Guinard, J., Descamps, Diane, Charpentier, C., Peytavin, G., Tremaux, P, Avettand-Fenoel, V., Soulie, C., Malet, I., Wirden, Marc, Marcelin, A, Calvez, V., Flandre, P., Costagliola, D, Morand-Joubert, Laurence, Lambert-Niclot, S., Fofana, D, Boukli, N., Delaugerre, C., Chaix, Marie-Laure, Mahjoub, Nadia, Amiel, Corinne, Giraudeau, G, Beby-Defaux, A., Plainchamp, D, Maillard, Anne, Alessandri-Gradt, E, Leoz, M, Plantier, Jean-Christophe, Gantner, P, Delagreverie, H, Fafi-Kremer, Samira, Fischer, P, Raymond, Stéphanie, Izopet, Jacques, Chiabrando, J, Stefic, Karl, Barin, F., Fajole, G, Burgault, O, Marque-Juillet, S, Service de Virologie [CHU Bichat], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Epidémiologie, stratégies thérapeutiques et virologie cliniques dans l'infection à VIH, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Immuno-Rhumatologie Moléculaire, Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Microbiologie cellulaire et moléculaire et pathogénicité (MCMP), Université Bordeaux Segalen - Bordeaux 2-Centre National de la Recherche Scientifique (CNRS), Université de Bordeaux (UB), virology, Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Centre de recherche sur l'hétéroepitaxie et ses applications (CRHEA), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA), Service de Virologie [CHU Caen], CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), CHU Clermont-Ferrand, Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Geneva University Hospital (HUG), Institut de biologie structurale (IBS - UMR 5075 ), Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Laboratoire de virologie [CHU Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Institut Hospitalier Universitaire Méditerranée Infection (IHU Marseille), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Laboratoire de Chimie Physique et Microbiologie pour les Matériaux et l'Environnement (LCPME), Institut de Chimie du CNRS (INC)-Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Service de virologie [CHU Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Hôtel-Dieu de Nantes, Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Radiologie [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU), Pharmacie de l'Hôpital Bichat, Centre de Recherches Pétrographiques et Géochimiques (CRPG), Institut national des sciences de l'Univers (INSU - CNRS)-Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Service de Virologie [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), CHU Saint-Antoine [AP-HP], Service de microbiologie [Saint-Louis], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Génétique et Ecologie des Virus, Génétique des Virus et Pathogénèse des Maladies Virales, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire de Virologie [CHU Saint-Louis], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Centre d'Immunologie et des Maladies Infectieuses (CIMI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Unité de Rétrovirologie, Hôpital Pontchaillou, Normandie Université (NU), Laboratoire de Virologie, CHU Strasbourg, Laboratoire de Virologie [Toulouse], CHU Toulouse [Toulouse], Service de bactériologie-virologie [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau, Centre national de référence du VIH INSERM U966, Université de Tours (UT), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Besançon, Université de Franche-Comté (UFC), Université Grenoble Alpes (UGA), Université Nice Sophia Antipolis (... - 2019) (UNS), Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), Unit for Virus Host-Cell Interactions [Grenoble] (UVHCI), Université Joseph Fourier - Grenoble 1 (UJF)-European Molecular Biology Laboratory [Grenoble] (EMBL)-Centre National de la Recherche Scientifique (CNRS), Institut de biologie structurale (IBS - UMR 5075), Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Grenoble Alpes (UGA)-Centre National de la Recherche Scientifique (CNRS), Institut Hospitalier Universitaire Méditerranée Infection (IHU AMU), Stress, Immunité, Pathogènes (SIMPA), Université de Lorraine (UL), Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Physiologie, Environnement et Génétique pour l'Animal et les Systèmes d'Elevage [Rennes] (PEGASE), AGROCAMPUS OUEST-Institut National de la Recherche Agronomique (INRA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], CHU Saint-Antoine [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Diderot - Paris 7 (UPD7), Centre d'Immunologie et de Maladies Infectieuses (CIMI), Université de Tours, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-IFR10, Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS), Service de virologie [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Hôpital Bretonneau-Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Diderot - Paris 7 (UPD7)
- Subjects
Male ,Etravirine ,HIV Infections ,Men who have sex with men ,Sexual and Gender Minorities ,chemistry.chemical_compound ,Pre-exposure prophylaxis ,0302 clinical medicine ,Pharmacology (medical) ,030212 general & internal medicine ,Phylogeny ,ComputingMilieux_MISCELLANEOUS ,0303 health sciences ,education.field_of_study ,Virulence ,biology ,[SDE.IE]Environmental Sciences/Environmental Engineering ,Middle Aged ,Viral Load ,3. Good health ,Integrase ,Infectious Diseases ,Rilpivirine ,Epidemiological Monitoring ,[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology ,Female ,France ,Viral load ,medicine.drug ,Adult ,Microbiology (medical) ,Genotype ,Anti-HIV Agents ,[SDE.MCG]Environmental Sciences/Global Changes ,Population ,Evolution, Molecular ,03 medical and health sciences ,Drug Resistance, Viral ,medicine ,Humans ,education ,Pharmacology ,030306 microbiology ,Genetic Variation ,Sequence Analysis, DNA ,[SDE.ES]Environmental Sciences/Environmental and Society ,Virology ,chemistry ,Mutation ,HIV-1 ,biology.protein ,[SDE.BE]Environmental Sciences/Biodiversity and Ecology - Abstract
ObjectivesPatients with primary HIV-1 infection (PHI) are a particular population, giving important insight about ongoing evolution of transmitted drug resistance-associated mutation (TDRAM) prevalence, HIV diversity and clustering patterns. We describe these evolutions of PHI patients diagnosed in France from 2014 to 2016.MethodsA total of 1121 PHI patients were included. TDRAMs were characterized using the 2009 Stanford list and the French ANRS algorithm. Viral subtypes and recent transmission clusters (RTCs) were also determined.ResultsPatients were mainly MSM (70%) living in the Paris area (42%). TDRAMs were identified among 10.8% of patients and rose to 18.6% when including etravirine and rilpivirine TDRAMs. Prevalences of PI-, NRTI-, first-generation NNRTI-, second-generation NNRTI- and integrase inhibitor-associated TDRAMs were 2.9%, 5.0%, 4.0%, 9.4% and 5.4%, respectively. In a multivariable analysis, age >40 years and non-R5 tropic viruses were associated with a >2-fold increased risk of TDRAMs. Regarding HIV diversity, subtype B and CRF02_AG (where CRF stands for circulating recombinant form) were the two main lineages (56% and 20%, respectively). CRF02_AG was associated with higher viral load than subtype B (5.83 versus 5.40 log10 copies/mL, P = 0.004). We identified 138 RTCs ranging from 2 to 14 patients and including overall 41% from the global population. Patients in RTCs were younger, more frequently born in France and more frequently MSM.ConclusionsSince 2007, the proportion of TDRAMs has been stable among French PHI patients. Non-B lineages are increasing and may be associated with more virulent CRF02_AG strains. The presence of large RTCs highlights the need for real-time cluster identification to trigger specific prevention action to achieve better control of the epidemic.
- Published
- 2019
24. Early Impairment of CD8+ T Cells Immune Response Against Epstein–Barr Virus (EBV) Antigens Associated with High Level of Circulating Mononuclear EBV DNA Load in HIV Infection
- Author
-
Legoff, Jérôme, Amiel, Corinne, Calisonni, Olivier, Fromentin, Delphine, Rajoely, Bakoliarisoa, Abuaf, Nisen, Tartour, Eric, Rozenbaum, Willy, Bélec, Laurent, and Nicolas, Jean-Claude
- Published
- 2004
- Full Text
- View/download PDF
25. Cytokine Analysis at the Single Cell Level and Lymphoproliferative Responses to Mycobacterial Antigens in HIV-1 Patients with Successful Virologic Response to Potent Antiretrovirals
- Author
-
Amiel, Corinne, Kusnierz, Jean-Pierre, Mouton, Yves, Rook, Graham, Stanford, John, Singh, Mahavir, Capron, Andre, and Bahr, George M.
- Published
- 2000
- Full Text
- View/download PDF
26. Clinical tolerance and immunologic effects after single or repeated administrations of the synthetic immunomodulator Murabutide in HIV-1-infected patients
- Author
-
Amiel, Corinne, La Tribonniere, Xavier de, Vidal, Vincent, Darcissac, Edith, Mouton, Yves, and Bahr, George M.
- Subjects
Epidemiology -- Statistics ,Epidemiology -- Research ,HIV patients -- Health aspects ,HIV patients -- Care and treatment ,HIV infection -- Prevention ,HIV infection -- Research ,HIV infection -- Health aspects ,Immunotherapy -- Analysis ,Immunotherapy -- Usage ,Anti-HIV agents -- Dosage and administration ,Genetic regulation -- Research ,Antiviral agents -- Physiological aspects ,Health - Abstract
Research has been conducted on the synthetic immunomodulator Murabutide which regulated antigen-presenting cell function. The potential use of this drug in HIV-1-infected patients undergoing antiretroviral therapy has been tested and the results are reported.
- Published
- 2002
27. New Kaposi’s sarcoma-associated herpesvirus variant in men who have sex with men associated with severe pathologies
- Author
-
Jary, Aude, primary, Leducq, Valentin, additional, Desire, Nathalie, additional, Petit, Héloïse, additional, Palich, Romain, additional, Joly, Véronique, additional, Canestri, Ana, additional, Gothland, Adélie, additional, Lambert-Niclot, Sidonie, additional, Surgers, Laure, additional, Amiel, Corinne, additional, Descamps, Diane, additional, Spano, Jean-Philippe, additional, Katlama, Christine, additional, Calvez, Vincent, additional, and Marcelin, Anne-Geneviève, additional
- Published
- 2020
- Full Text
- View/download PDF
28. Factors predictive of virological failure on atazanavir in 310 HIV-infected patients
- Author
-
Lescure, François-Xavier, Poirier, Jean-Marie, Meynard, Jean-Luc, Guiard-Schmid, Jean-Baptiste, Zouai, Ouahiba, Bonnard, Philippe, Slama, Laurence, Amiel, Corinne, Girard, Pierre-Marie, and Pialoux, Gilles
- Published
- 2010
- Full Text
- View/download PDF
29. Uncommon Detection of Mixed HCV Genotype Infections in Recently Infected Men Who Have Sex with Men
- Author
-
Nguyen, Thuy, primary, Delaugerre, Constance, additional, Valantin, Marc-Antoine, additional, Amiel, Corinne, additional, Netzer, Emmanuelle, additional, L'Yavanc, Thomas, additional, Ohayon, Michel, additional, Israel, Gérard, additional, Valin, Nadia, additional, Day, Nesrine, additional, Kreplak, Georges, additional, Pialoux, Gilles, additional, Calvez, Vincent, additional, Molina, Jean-Michel, additional, Marcelin, Anne-Geneviève, additional, and Todesco, Eve, additional
- Published
- 2019
- Full Text
- View/download PDF
30. A new insertion in the HIV-1 reverse transcriptase gene inducing major resistance to non-nucleoside reverse transcriptase inhibitors
- Author
-
Amiel, Corinne, Desire, Nathalie, Schneider, Veronique, Delphin, Nathalie, Race, Ester, Clavel, Françoise, Piolot, Tristan, Dam, Elisabeth, Rozenbaum, Willy, and Nicolas, Jean-Claude
- Published
- 2005
- Full Text
- View/download PDF
31. Factors associated with the emergence of integrase resistance mutations in patients failing dual or triple integrase inhibitor-based regimens in a French national survey.
- Author
-
Marcelin, Anne-Genevieve, Charpentier, Charlotte, Bellecave, Pantxika, Abdi, Basma, Chaix, Marie-Laure, Ferre, Virginie, Raymond, Stephanie, Fofana, Djeneba, Bocket, Laurence, Mirand, Audrey, Guillou-Guillemette, Helene Le, Montes, Brigitte, Amiel, Corinne, Pallier, Coralie, Fafi-Kremer, Samira, Monte, Anne De, Alessandri-Gradt, Elodie, Scholtes, Caroline, Maillard, Anne, and Jeulin, Helene
- Subjects
DRUG accessibility ,GENOTYPES ,UNIVARIATE analysis ,STATISTICAL significance ,MULTIVARIATE analysis ,VIRAL load ,PROTEINS ,HIV infections ,PYRIDINE ,RESEARCH ,HIV integrase inhibitors ,GENETIC mutation ,HETEROCYCLIC compounds ,RESEARCH methodology ,MEDICAL cooperation ,EVALUATION research ,COMPARATIVE studies ,RESEARCH funding ,DRUG resistance in microorganisms ,HIV ,PHARMACODYNAMICS - Abstract
Background: Successful 2-drug regimens (2DRs) for HIV were made possible by the availability of drugs combining potency and tolerability with a high genetic barrier to resistance. How these deal with resistance development/re-emergence, compared with 3DRs, is thus of paramount importance.Materials and Methods: A national survey including patients who were either naive or experienced with any 2DR or 3DR but failing integrase strand transfer inhibitor (INSTI)-containing regimens [two consecutive plasma viral load (VL) values >50 copies/mL] was conducted between 2014 and 2019. Genotypic resistance tests were interpreted with the v28 ANRS algorithm.Results: Overall, 1104 patients failing any INSTI-containing regimen (2DRs, n = 207; 3DRs, n = 897) were analysed. Five hundred and seventy-seven (52.3%) patients were infected with a B subtype and 527 (47.3%) with non-B subtypes. Overall, 644 (58%) patients showed no known integrase resistance mutations at failure. In multivariate analysis, factors associated with the emergence of at least one integrase mutation were: high VL at failure (OR = 1.24 per 1 log10 copies/mL increase); non-B versus B subtype (OR = 1.75); low genotypic sensitivity score (GSS) (OR = 0.10 for GSS = 2 versus GSS = 0-0.5); and dolutegravir versus raltegravir (OR = 0.46). Although 3DRs versus 2DRs reached statistical significance in univariate analysis (OR = 0.59, P = 0.007), the variable is not retained in the final model.Conclusions: This study is one of the largest studies characterizing integrase resistance in patients failing any INSTI-containing 2DR or 3DR in routine clinical care and reveals factors associated with emergence of integrase resistance that should be taken into consideration in clinical management. No difference was evidenced between patients receiving a 2DR or a 3DR. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
32. Clinical and immunological effects of a 6 week immunotherapy cycle with murabutide in HIV-1 patients with unsuccessful long-term antiretroviral treatment
- Author
-
Bahr, George M., De La Tribonnière, Xavier, Darcissac, Edith, Ajana, Faïza, Bocket, Laurence, Sissoko, Daouda, Yazdanpanah, Yazdan, Dewulf, Joëlle, Amiel, Corinne, and Mouton, Yves
- Published
- 2003
33. Symptomatic hyperlactataemia: an emerging complication of antiretroviral therapy
- Author
-
Gérard, Yann, Maulin, Laurence, Yazdanpanah, Yazdan, De La Tribonnière, Xavier, Amiel, Corinne, Maurage, Claude-Alain, Robin, Sophie, Sablonnière, Bernard, Dhennain, Chantal, and Mouton, Yves
- Published
- 2000
34. Emerging resistance mutations in PI-naive patients failing an atazanavir-based regimen (ANRS multicentre observational study)
- Author
-
Lambert-Niclot, L, Grude, C, Chaix, L., Charpentier, L, Reigadas, C, Le Guillou-Guillemette, L, Rodallec, C, Maillard, Pascale, Dufayard, C, Mourez, C, Mirand, C, Guinard, L, Montes, S, Vallet, L, Marcelin, Marc, Descamps, L, Flandre, C, Delaugerre, L, Alloui, Chakib, Descamps, Diane, Charpentier, Charlotte, Visseaux, Benoit, Krivine, Anne, Bouviers-Alias, Ali, Pallier, Coralie, Soulié, Cathia, Wirden, Marc, Marcelin, Anne, Calvez, Vincent, Morand, Laurence, Lambert-Niclot, Sidonie, Fofana, Djeneba, Mahjoub, Nadia, Delaugerre, Constance, Chaix, Marie, Amiel, Corinne, Schneider, Veronique, Roussel, Catherine, Le Guillou-Guillemette, Hélène, Courdavault, Laurence, Reigadas, Sandrine, Recordon-Pinson, Patricia, Fleury, Hervé, Vallet, Sophie, Dina, Julia, Vabret, Astrid, Mirand, Audrey, Henquell, Cécile, Auvray, Christelle, de Rougemont, Alexis, Giraudon, Helene, Si-Mohammed, Ali, Mathez, Dominique, Signori-Schmuck, Anne, Morand, Patrice, Bocket, Laurence, Trabaud, Anne, Montes, Brigitte, Le Guen, Laura, Rodallec, Audrey, Ferré, Virginie, Jeulin, Hélène, SCHVOERER, Evelyne, Dufayard, Jacqueline, Allardet-Servent, Annick, carles, Marie, Guinard, Jérôme, Guigon, Aurélie, Giraudeau, Genevieve, Beby-Defaux, Agnès, Maillard, Anne, Plantier, Jean Christophe, Leoz, Marie, Mourez, Thomas, Bourlet, Thomas, Fafi-Kremer, Samira, Chiabrando, Julie, Raymond, Stéphanie, Izopet, Jacques, Barin, Francis, Marque-Juillet, Stéphanie, Yerly, Sabine, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Pierre et Marie Curie - Paris 6 - UFR de Médecine Pierre et Marie Curie (UPMC), Université Pierre et Marie Curie - Paris 6 (UPMC), Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Hôpital Pellegrin, CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Centre hospitalier universitaire de Nantes (CHU Nantes), Hôpital Pontchaillou, Centre Hospitalier Universitaire de Nice (CHU Nice), CHU Rouen, Normandie Université (NU), CHU Clermont-Ferrand, Centre Hospitalier Régional d'Orléans (CHRO), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Hôpital de la Cavale Blanche - CHRU Brest (CHU - BREST ), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Laboratoire Bordelais de Recherche en Informatique (LaBRI), Université de Bordeaux (UB)-Centre National de la Recherche Scientifique (CNRS)-École Nationale Supérieure d'Électronique, Informatique et Radiocommunications de Bordeaux (ENSEIRB), Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-IFR10, Service de virologie [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Epidémiologie, stratégies thérapeutiques et virologie cliniques dans l'infection à VIH, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Département de Mathématiques et Applications - ENS Paris (DMA), École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS), Département d'Astrophysique, de physique des Particules, de physique Nucléaire et de l'Instrumentation Associée (DAPNIA), Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Laboratoire de Virologie [CHU Saint-Louis], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Génétique et Ecologie des Virus, Génétique des Virus et Pathogénèse des Maladies Virales, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), UFR des Sciences de Santé (Université de Bourgogne), Université de Bourgogne (UB), CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hémodynamique, Interaction Fibrose et Invasivité tumorales Hépatiques (HIFIH), Université d'Angers (UA), Centre Hospitalier Victor Dupouy, Microbiologie cellulaire et moléculaire et pathogénicité (MCMP), Université Bordeaux Segalen - Bordeaux 2-Centre National de la Recherche Scientifique (CNRS), CHU Bordeaux [Bordeaux], Laboratoire Universitaire de Biodiversité et Ecologie Microbienne (LUBEM), Université de Brest (UBO), Laboratoire de Virologie Humaine et Moléculaire [Caen], CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Groupe de Recherche sur l'Adaptation Microbienne (GRAM 2.0), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Université de Caen Normandie (UNICAEN), Laboratoire Microorganismes : Génome et Environnement (LMGE), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre National de la Recherche Scientifique (CNRS), Laboratoire de sérologie-virologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Hôpital Raymond Poincaré [AP-HP], Institut de biologie structurale (IBS - UMR 5075 ), Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS), Département de virologie [Grenoble], Centre Hospitalier Universitaire [Grenoble] (CHU), Service de Virologie [Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Epidémiologie, Démographie et Sciences Sociales: santé reproductive, sexualité et infection à VIH (Inserm U569), Epidémiologie, sciences sociales, santé publique (IFR 69), Université Paris 1 Panthéon-Sorbonne (UP1)-Université Paris-Sud - Paris 11 (UP11)-École des hautes études en sciences sociales (EHESS)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris 1 Panthéon-Sorbonne (UP1)-Université Paris-Sud - Paris 11 (UP11)-École des hautes études en sciences sociales (EHESS)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut national d'études démographiques (INED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire de Chimie Physique et Microbiologie pour les Matériaux et l'Environnement (LCPME), Institut de Chimie du CNRS (INC)-Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Observatoire des Programmes Communautaires de Développement Rural (US ODR), Institut National de la Recherche Agronomique (INRA), Institut Pasteur de Nouvelle-Calédonie, Réseau International des Instituts Pasteur (RIIP), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Ecophysiologie Végétale, Agronomie et Nutritions (EVA), Institut National de la Recherche Agronomique (INRA)-Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU), Groupe Immunité des Muqueuses et Agents Pathogènes (GIMAP), Université Jean Monnet [Saint-Étienne] (UJM), Interaction virus-hôte et maladies du foie, Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Claude de Préval (ICP), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Toulouse [Toulouse]-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées, Université de Tours (UT), Centre Hospitalier de Versailles André Mignot (CHV), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Université de Bordeaux (UB)-École Nationale Supérieure d'Électronique, Informatique et Radiocommunications de Bordeaux (ENSEIRB)-Centre National de la Recherche Scientifique (CNRS), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), École normale supérieure - Paris (ENS-PSL), Microbiologie Fondamentale et Pathogénicité (MFP), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Recherche Agronomique (INRA), Université Jean Monnet - Saint-Étienne (UJM), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Diderot - Paris 7 (UPD7), Université de Tours, Service de Virologie [CHU Pitié-Salpêtrière], Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Lycée agricole La Touche, Hôpital Bichat - Claude Bernard, Centre National de la Recherche Scientifique (CNRS)-École Nationale Supérieure d'Électronique, Informatique et Radiocommunications de Bordeaux (ENSEIRB)-Université Sciences et Technologies - Bordeaux 1-Université Bordeaux Segalen - Bordeaux 2, Memo-Flu-ARDS Study Group, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], École normale supérieure - Paris (ENS Paris)-Centre National de la Recherche Scientifique (CNRS), CHU Pitié-Salpêtrière [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), CHU Tenon [APHP], Hôpital d'Argenteuil, Laboratoire Microorganismes : Génome et Environnement - Clermont Auvergne (LMGE), Université Clermont Auvergne (UCA)-Centre National de la Recherche Scientifique (CNRS), AP-HP Hôpital Raymond Poincaré [Garches], Unit for Virus Host-Cell Interactions [Grenoble] (UVHCI), Université Joseph Fourier - Grenoble 1 (UJF)-European Molecular Biology Laboratory [Grenoble] (EMBL)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de virologie moléculaire et structurale, CHU Grenoble, Laboratoire de virologie [CHU Lille], Université Panthéon-Sorbonne (UP1)-Université Paris-Sud - Paris 11 (UP11)-École des hautes études en sciences sociales (EHESS)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Panthéon-Sorbonne (UP1)-Université Paris-Sud - Paris 11 (UP11)-École des hautes études en sciences sociales (EHESS)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut national d'études démographiques (INED), Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Centre national de référence du VIH INSERM U966, Centre Hospitalier de Versailles (CHV), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
- Subjects
0301 basic medicine ,Microbiology (medical) ,Adult ,Male ,medicine.medical_specialty ,030106 microbiology ,Atazanavir Sulfate ,HIV Infections ,Emtricitabine ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Abacavir ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Internal medicine ,Drug Resistance, Viral ,medicine ,Humans ,Pharmacology (medical) ,030212 general & internal medicine ,Treatment Failure ,Tenofovir ,ComputingMilieux_MISCELLANEOUS ,Retrospective Studies ,Pharmacology ,business.industry ,virus diseases ,Lamivudine ,HIV Protease Inhibitors ,Middle Aged ,Viral Load ,Resistance mutation ,Dideoxynucleosides ,3. Good health ,Atazanavir ,Regimen ,Drug Combinations ,Infectious Diseases ,Mutation ,[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology ,HIV-1 ,Ritonavir ,business ,Viral load ,medicine.drug - Abstract
Background Atazanavir is a PI widely used as a third agent in combination ART. We aimed to determine the prevalence and the patterns of resistance in PI-naive patients failing on an atazanavir-based regimen. Methods We analysed patients failing on an atazanavir-containing regimen used as a first line of PI therapy. We compared the sequences of reverse transcriptase and protease before the introduction of atazanavir and at failure [two consecutive viral loads (VLs) >50 copies/mL]. Resistance was defined according to the 2014 Agence Nationale de Recherche sur le SIDA et les Hepatites Virales (ANRS) algorithm. Results Among the 113 patients, atazanavir was used in the first regimen in 71 (62.8%) patients and in the first line of a PI-based regimen in 42 (37.2%). Atazanavir was boosted with ritonavir in 95 (84.1%) patients and combined with tenofovir/emtricitabine or lamivudine (n = 81) and abacavir/lamivudine or emtricitabine (n = 22). At failure, median VL was 3.05 log10 copies/mL and the median CD4+ T cell count was 436 cells/mm3. The median time on atazanavir was 21.2 months. At failure, viruses were considered resistant to atazanavir in four patients (3.5%) with the selection of the following major atazanavir-associated mutations: I50L (n = 1), I84V (n = 2) and N88S (n = 1). Other emergent PI mutations were L10V, G16E, K20I/R, L33F, M36I/L, M46I/L, G48V, F53L, I54L, D60E, I62V, A71T/V, V82I/T, L90M and I93L/M. Emergent NRTI substitutions were detected in 21 patients: M41L (n = 2), D67N (n = 3), K70R (n = 1), L74I/V (n = 3), M184V/I (n = 16), L210W (n = 1), T215Y/F (n = 3) and K219Q/E (n = 2). Conclusions Resistance to atazanavir is rare in patients failing the first line of an atazanavir-based regimen according to the ANRS. Emergent NRTI resistance-associated mutations were reported in 18% of patients.
- Published
- 2018
35. Pre-emptive rituximab treatment for Epstein–Barr virus reactivation after allogeneic hematopoietic stem cell transplantation is a worthwhile strategy in high-risk recipients: a comparative study for immune recovery and clinical outcomes
- Author
-
Stocker, Nicolas, primary, Labopin, Myriam, additional, Boussen, Inès, additional, Paccoud, Olivier, additional, Bonnin, Agnès, additional, Malard, Florent, additional, Amiel, Corinne, additional, Gozlan, Joël, additional, Battipaglia, Giorgia, additional, Duléry, Rémy, additional, Giannotti, Federica, additional, Ruggeri, Annalisa, additional, Gaugler, Béatrice, additional, Mohty, Mohamad, additional, and Brissot, Eolia, additional
- Published
- 2019
- Full Text
- View/download PDF
36. High clustering of acute HCV infections and high rate of associated STIs among Parisian HIV-positive male patients
- Author
-
Todesco, Eve, primary, Day, Nesrine, additional, Amiel, Corinne, additional, Elaerts, Stéphane, additional, Schneider, Véronique, additional, Roudière, Laurent, additional, Hué, Stéphane, additional, Liotier, Jean-Yves, additional, Bottero, Julie, additional, L'Yavanc, Thomas, additional, Ohayon, Michel, additional, Gosset, Daniel, additional, Thibault, Vincent, additional, Surgers, Laure, additional, Chas, Julie, additional, Akhavan, Sepideh, additional, Velter, Annie, additional, Katlama, Christine, additional, Kreplak, Georges, additional, Marcelin, Anne-Geneviève, additional, and Valantin, Marc-Antoine, additional
- Published
- 2019
- Full Text
- View/download PDF
37. Extra-cellular release and blood diffusion of BART viral micro-RNAs produced by EBV-infected nasopharyngeal carcinoma cells
- Author
-
Baconnais Sonia, Amiel Corinne, Schneider Véronique, Témam Stéphane, Lang Philippe, Guigay Joël, Vérillaud Benjamin, Klibi Jihène, Bombik Izabela, Gelin Aurore, Gourzones Claire, Jimenez Anne-Sophie, and Busson Pierre
- Subjects
Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Background Nasopharyngeal carcinoma (NPC) is a human epithelial malignancy consistently associated with the Epstein-Barr virus. The viral genome is contained in the nuclei of all malignant cells with abundant transcription of a family of viral microRNAs called BART miRNAs. MicroRNAs are well known intra-cellular regulatory elements of gene expression. In addition, they are often exported in the extra-cellular space and sometimes transferred in recipient cells distinct from the producer cells. Extra-cellular transport of the microRNAs is facilitated by various processes including association with protective proteins and packaging in secreted nanovesicles called exosomes. Presence of microRNAS produced by malignant cells has been reported in the blood and saliva of tumor-bearing patients, especially patients diagnosed with glioblastoma or ovarian carcinoma. In this context, it was decided to investigate extra-cellular release of BART miRNAs by NPC cells and their possible detection in the blood of NPC patients. To address this question, we investigated by quantitative RT-PCR the status of 5 microRNAs from the BART family in exosomes released by NPC cells in vitro as well as in plasma samples from NPC xenografted nude mice and NPC patients. Results We report that the BART miRNAs are released in the extra-cellular space by NPC cells being associated, at least to a large extent, with secreted exosomes. They are detected with a good selectivity in plasma samples from NPC xenografted nude mice as well as NPC patients. Conclusions Viral BART miRNAs are secreted by NPC cells in vitro and in vivo. They have enough stability to diffuse from the tumor site to the peripheral blood. This study provides a basis to explore their potential as a source of novel tumor biomarkers and their possible role in communications between malignant and non-malignant cells.
- Published
- 2010
- Full Text
- View/download PDF
38. Surveillance of HIV-1 primary infections in France from 2014 to 2016: toward stable resistance, but higher diversity, clustering and virulence?
- Author
-
Visseaux, Benoit, Assoumou, Lambert, Mahjoub, Nadia, Grude, Maxime, Trabaud, Mary-Anne, Raymond, Stéphanie, Wirden, Marc, Morand-Joubert, Laurence, Roussel, Catherine, Montes, Brigitte, Bocket, Laurence, Fafi-Kremer, Samira, Amiel, Corinne, Monte, Anne De, Stefic, Karl, Pallier, Coralie, Tumiotto, Camille, Maillard, Anne, Vallet, Sophie, and Ferre, Virginie
- Subjects
INFECTION ,HIV ,NON-nucleoside reverse transcriptase inhibitors ,VIRAL load ,NUCLEOSIDE reverse transcriptase inhibitors ,HIV infection epidemiology ,ANTI-HIV agents ,HIV infections ,RESEARCH ,GENETICS ,BIOLOGICAL evolution ,SEQUENCE analysis ,GENETIC mutation ,RESEARCH methodology ,EPIDEMIOLOGY ,MEDICAL cooperation ,EVALUATION research ,COMPARATIVE studies ,GENOTYPES ,DRUG resistance in microorganisms ,MICROBIAL virulence ,PHARMACODYNAMICS - Abstract
Objectives: Patients with primary HIV-1 infection (PHI) are a particular population, giving important insight about ongoing evolution of transmitted drug resistance-associated mutation (TDRAM) prevalence, HIV diversity and clustering patterns. We describe these evolutions of PHI patients diagnosed in France from 2014 to 2016.Methods: A total of 1121 PHI patients were included. TDRAMs were characterized using the 2009 Stanford list and the French ANRS algorithm. Viral subtypes and recent transmission clusters (RTCs) were also determined.Results: Patients were mainly MSM (70%) living in the Paris area (42%). TDRAMs were identified among 10.8% of patients and rose to 18.6% when including etravirine and rilpivirine TDRAMs. Prevalences of PI-, NRTI-, first-generation NNRTI-, second-generation NNRTI- and integrase inhibitor-associated TDRAMs were 2.9%, 5.0%, 4.0%, 9.4% and 5.4%, respectively. In a multivariable analysis, age >40 years and non-R5 tropic viruses were associated with a >2-fold increased risk of TDRAMs. Regarding HIV diversity, subtype B and CRF02_AG (where CRF stands for circulating recombinant form) were the two main lineages (56% and 20%, respectively). CRF02_AG was associated with higher viral load than subtype B (5.83 versus 5.40 log10 copies/mL, P=0.004). We identified 138 RTCs ranging from 2 to 14 patients and including overall 41% from the global population. Patients in RTCs were younger, more frequently born in France and more frequently MSM.Conclusions: Since 2007, the proportion of TDRAMs has been stable among French PHI patients. Non-B lineages are increasing and may be associated with more virulent CRF02_AG strains. The presence of large RTCs highlights the need for real-time cluster identification to trigger specific prevention action to achieve better control of the epidemic. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
39. Targeted HIV Screening in Eight Emergency Departments: The DICI-VIH Cluster-Randomized Two-Period Crossover Trial
- Author
-
Leblanc, Judith, primary, Hejblum, Gilles, additional, Costagliola, Dominique, additional, Durand-Zaleski, Isabelle, additional, Lert, France, additional, de Truchis, Pierre, additional, Verbeke, Geert, additional, Rousseau, Alexandra, additional, Piquet, Hélène, additional, Simon, François, additional, Pateron, Dominique, additional, Simon, Tabassome, additional, Crémieux, Anne-Claude, additional, Duchêne, Gaëlle, additional, Jegou, Carole, additional, Adnet, Frédéric, additional, Bouchaud, Olivier, additional, Alloui, Chakib, additional, Jauneau, Christine, additional, Troisvallets, Didier, additional, Vandemeulebroucke, Eric, additional, Fossoux, Nadia, additional, Raphaël, Maurice, additional, Vincent-Cassy, Christophe, additional, Quertainmont, Yann, additional, Goujard, Cécile, additional, Pallier, Coralie, additional, Vega, Aglavène, additional, Renaud, Bertrand, additional, Salmon, Dominique, additional, Krivine, Anne, additional, Bastide, Théophile, additional, Galichon, Bertrand, additional, Plaisance, Patrick, additional, Morgand, Marjolaine, additional, Maylin, Sarah, additional, Bercot, Béatrice, additional, Campa, Pauline, additional, Valin, Nadia, additional, Boukli, Narjis, additional, Morand-Joubert, Laurence, additional, Verbrugghe, Rachel, additional, Dautheville, Sandrine, additional, Ray, Patrick, additional, Lebrette, Marie-Gisèle, additional, Amiel, Corinne, additional, Lancien, Cécile, additional, Doumenc, Benoit, additional, Khuong, Marie-Aude, additional, Gros, Isabelle, additional, Mutuon, Pierre, additional, d’Almeida, Kayigan, additional, Fromentin, Hélène, additional, Martin, Maria, additional, Cossé, Charlotte, additional, and Burnet, Espérie, additional
- Published
- 2018
- Full Text
- View/download PDF
40. Usefulness of Kaposi's Sarcoma-Associated Herpesvirus (KSHV) DNA Viral Load in Whole Blood for Diagnosis and Monitoring of KSHV-Associated Diseases
- Author
-
Jary, Aude, primary, Leducq, Valentin, additional, Palich, Romain, additional, Gothland, Adélie, additional, Descamps, Diane, additional, Joly, Véronique, additional, Lambert-Niclot, Sidonie, additional, Amiel, Corinne, additional, Canestri, Ana, additional, Mirand, Audrey, additional, Gault, Elyanne, additional, Vabret, Astrid, additional, Valantin, Marc-Antoine, additional, Katlama, Christine, additional, Calvez, Vincent, additional, Dupin, Nicolas, additional, Spano, Jean-Philippe, additional, and Marcelin, Anne-Geneviève, additional
- Published
- 2018
- Full Text
- View/download PDF
41. Phenotypic analysis of HIV-1 E157Q integrase polymorphism and impact on virological outcome in patients initiating an integrase inhibitor-based regimen
- Author
-
Charpentier, Charlotte, primary, Malet, Isabelle, additional, Andre-Garnier, Elisabeth, additional, Storto, Alexandre, additional, Bocket, Laurence, additional, Amiel, Corinne, additional, Morand-Joubert, Laurence, additional, Tumiotto, Camille, additional, Nguyen, Thuy, additional, Maillard, Anne, additional, Rodallec, Audrey, additional, Leoz, Marie, additional, Montes, Brigitte, additional, Schneider, Véronique, additional, Plantier, Jean-Christophe, additional, Dina, Julia, additional, Pallier, Coralie, additional, Mirand, Audrey, additional, Roussel, Catherine, additional, Signori-Schmuck, Anne, additional, Raymond, Stéphanie, additional, Calvez, Vincent, additional, Delaugerre, Constance, additional, Marcelin, Anne-Geneviève, additional, and Descamps, Diane, additional
- Published
- 2018
- Full Text
- View/download PDF
42. Long-term AIDS-related PCNSL outcomes with HD-MTX and combined antiretroviral therapy
- Author
-
Moulignier, Antoine, primary, Lamirel, Cédric, additional, Picard, Hervé, additional, Lebrette, Marie-Gisèle, additional, Amiel, Corinne, additional, Hamidi, Mohammed, additional, Polivka, Marc, additional, Mikol, Jacqueline, additional, Cochereau, Isabelle, additional, and Pialoux, Gilles, additional
- Published
- 2017
- Full Text
- View/download PDF
43. Antiretroviral-treated HIV-1 patients can harbour resistant viruses in CSF despite an undetectable viral load in plasma
- Author
-
Soulie, Cathia, primary, Grudé, Maxime, additional, Descamps, Diane, additional, Amiel, Corinne, additional, Morand-Joubert, Laurence, additional, Raymond, Stéphanie, additional, Pallier, Coralie, additional, Bellecave, Pantxika, additional, Reigadas, Sandrine, additional, Trabaud, Mary-Anne, additional, Delaugerre, Constance, additional, Montes, Brigitte, additional, Barin, Francis, additional, Ferré, Virginie, additional, Jeulin, Hélène, additional, Alloui, Chakib, additional, Yerly, Sabine, additional, Signori-Schmuck, Anne, additional, Guigon, Aurélie, additional, Fafi-Kremer, Samira, additional, Haïm-Boukobza, Stéphanie, additional, Mirand, Audrey, additional, Maillard, Anne, additional, Vallet, Sophie, additional, Roussel, Catherine, additional, Assoumou, Lambert, additional, Calvez, Vincent, additional, Flandre, Philippe, additional, and Marcelin, Anne-Geneviève, additional
- Published
- 2017
- Full Text
- View/download PDF
44. Mesure et interprétation des charges virales dans les infections à herpèsvirus humains (cytomégalovirus, virus Epstein-Barr, herpèsvirus humains 6 et 8)
- Author
-
Mazeron, Marie-Christine, primary, Amiel, Corinne, additional, and Agut, Henri, additional
- Published
- 2016
- Full Text
- View/download PDF
45. Resistance to integrase inhibitors: a national study in HIV-1-infected treatment-naive and -experienced patients.
- Author
-
Marcelin, Anne-Genevieve, Grude, Maxime, Charpentier, Charlotte, Bellecave, Pantxika, Guen, Laura Le, Pallier, Coralie, Raymond, Stéphanie, Mirand, Audrey, Bocket, Laurence, Fofana, Djeneba Bocar, Delaugerre, Constance, Nguyen, Thuy, Montès, Brigitte, Jeulin, Hélène, Mourez, Thomas, Fafi-Kremer, Samira, Amiel, Corinne, Roussel, Catherine, Dina, Julia, and Trabaud, Mary-Anne
- Subjects
INTEGRASE inhibitors ,ANTIRETROVIRAL agents ,GENOTYPES ,INTEGRASES - Abstract
Objectives: To describe integrase strand transfer inhibitor (INSTI) resistance profiles and factors associated with resistance in antiretroviral-naive and -experienced patients failing an INSTI-based regimen in clinical practice.Methods: Data were collected from patients failing an INSTI-containing regimen in a multicentre French study between 2014 and 2017. Failure was defined as two consecutive plasma viral loads (VL) >50 copies/mL. Reverse transcriptase, protease and integrase coding regions were sequenced at baseline and failure. INSTI resistance-associated mutations (RAMs) included in the Agence Nationale de Recherches sur le SIDA genotypic algorithm were investigated.Results: Among the 674 patients, 359 were failing on raltegravir, 154 on elvitegravir and 161 on dolutegravir therapy. Overall, 90% were experienced patients and 389 (58%) patients showed no INSTI RAMs at failure. The strongest factors associated with emergence of at least one INSTI mutation were high VL at failure (OR = 1.2 per 1 log10 copies/mL increase) and low genotypic sensitivity score (GSS) (OR = 0.08 for GSS ≥3 versus GSS = 0-0.5). Patients failing dolutegravir also had significantly fewer INSTI RAMs at failure than patients failing raltegravir (OR = 0.57, P = 0.02) or elvitegravir (OR = 0.45, P = 0.005). Among the 68 patients failing a first-line regimen, 11/41 (27%) patients on raltegravir, 7/18 (39%) on elvitegravir and 0/9 on dolutegravir had viruses with emergent INSTI RAMs at failure.Conclusions: These results confirmed the robustness of dolutegravir regarding resistance selection in integrase in the case of virological failure in routine clinical care. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
46. Drug resistance and tropism as markers of the dynamics of HIV-1 DNA quasispecies in blood cells of heavily pretreated patients who achieved sustained virological suppression
- Author
-
Gantner, Pierre, primary, Morand-Joubert, Laurence, additional, Sueur, Charlotte, additional, Raffi, François, additional, Fagard, Catherine, additional, Lascoux-Combe, Caroline, additional, Salmon, Dominique, additional, Amiel, Corinne, additional, Lambert-Niclot, Sidonie, additional, Fofana, Djeneba Bocar, additional, Viard, Jean-Paul, additional, Fafi-Kremer, Samira, additional, Rouzioux, Christine, additional, Avettand-Fenoel, Véronique, additional, and Ghosn, Jade, additional
- Published
- 2015
- Full Text
- View/download PDF
47. Aspects actuels des infections par le virus de l'immunodéficience humaine et par le virus lymphotrophique humain chez l'homme, la femme et l'enfant et de leur traitement par les antirétroviraux.
- Author
-
Lebrette, Marie-Gisèle and Amiel, Corinne
- Abstract
HIV (human immunodeficiency virus) and HTLV (human T lymphotropic virus) are zoonotic infections, due to transmission of retroviruses of simian origins to human people. Contamination routes share similarities for blood and sexual transmission, but mother-to-child transmission differs: mostly at the end of pregnancy, during childbirth or breastfeeding for HIV, prolonged breastfeeding for HTLV. The high seroprevalence for both viruses in West Africa and carribean regions contributes to the majority of HTLV infections found in France. Most of HIV-infected patients receive antiretroviral therapy to prevent transmission (in adults and mother to child transmission) and reduce immunodeficiency, whereas no specific treatment exists for HTLV infected patients. HTLV-associated diseases (leukemia/lymphoma or myeopathy) concerns less than 7 % of HTLV infected-patients and zidovudine, interferon or other immunotherapies are used for associated diseases such a as leukemia/lymphomia or myeolopathy. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
48. Phenotypic analysis of HIV-1 E157Q integrase polymorphism and impact on virological outcome in patients initiating an integrase inhibitor-based regimen.
- Author
-
Charpentier, Charlotte, Malet, Isabelle, Andre-Garnier, Elisabeth, Storto, Alexandre, Bocket, Laurence, Amiel, Corinne, Morand-Joubert, Laurence, Tumiotto, Camille, Nguyen, Thuy, Maillard, Anne, Rodallec, Audrey, Leoz, Marie, Montes, Brigitte, Schneider, Véronique, Plantier, Jean-Christophe, Dina, Julia, Pallier, Coralie, Mirand, Audrey, Roussel, Catherine, and Signori-Schmuck, Anne
- Subjects
HIV infection genetics ,RALTEGRAVIR ,HIV integrase inhibitors ,GENETIC polymorphisms ,HIV ,HIV infections ,MICROBIAL sensitivity tests ,GENETIC mutation ,PHENOTYPES ,VIRAL load ,TREATMENT effectiveness ,SEQUENCE analysis ,THERAPEUTICS - Abstract
Objectives: To assess the phenotypic susceptibility of the E157Q polymorphism in HIV-1 integrase (IN) and the virological outcome of patients infected with E157Q-mutated virus initiating an IN inhibitor (INI)-based regimen.Methods: This was a multicentre study assessing IN sequences from INI-naive patients among 17 French HIV clinical centres. E157Q site-directed mutants in pNL4.3 and pCRF02_AG contexts were assessed in a recombinant phenotypic assay.Results: Prevalence of the E157Q polymorphism was 2.7% among 8528 IN sequences from INI-naive patients and its distribution was 1.7%, 5.6% and 2.2% in B, CRF02_AG and various non-B subtypes, respectively. Thirty-nine INI-naive patients with E157Q-mutated virus initiated an INI-based regimen. Among them, 15 had a viral load (VL) <50 copies/mL at initiation and virological suppression was maintained during the first year of follow-up in all but two exhibiting a viral blip. Twenty-four patients had a VL > 50 copies/mL at the time of INI-based regimen initiation. Among them eight were receiving a first-line regimen and the only two patients who did not reach VL < 50 copies/mL at week 24 were receiving elvitegravir. The 16 remaining patients were ART experienced in virological failure with drug-resistant viruses displaying several virological outcomes independently of the genotypic susceptibility score. Phenotypic analyses showed a fold change in EC50 of 0.6, 0.9 and 1.9 for raltegravir, dolutegravir and elvitegravir, respectively, in a subtype B context, and 1.1, 1.9 and 2.4 for raltegravir, dolutegravir and elvitegravir, respectively, in a CRF02_AG context.Conclusions: Assessment of virological response in 39 patients initiating an INI-based regimen with E157Q-mutated virus, in combination with phenotypic analysis, suggests that particular attention should be paid to antiretroviral-naive patients and dolutegravir should be preferentially used in these patients. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
49. Combined Linkage and Association Studies Show that HLA Class II Variants Control Levels of Antibodies against Epstein-Barr Virus Antigens
- Author
-
Pedergnana, Vincent, primary, Syx, Laurène, additional, Cobat, Aurélie, additional, Guergnon, Julien, additional, Brice, Pauline, additional, Fermé, Christophe, additional, Carde, Patrice, additional, Hermine, Olivier, additional, Pendeven, Catherine Le-, additional, Amiel, Corinne, additional, Taoufik, Yassine, additional, Alcaïs, Alexandre, additional, Theodorou, Ioannis, additional, Besson, Caroline, additional, and Abel, Laurent, additional
- Published
- 2014
- Full Text
- View/download PDF
50. Specific detection of Epstein-Barr virus microRNAs in plasma samples from nasopharyngeal carcinoma patients: Correlation with tumor mass assessed by MRI.
- Author
-
Ferrand, francois-Regis, primary, Gatolliat, charles-Henry, additional, Bidault, Francois, additional, Verillaud, Benjamin, additional, Gelin, Aurore, additional, Jimenez-Pailhes, anne-Sophie, additional, Amiel, Corinne, additional, Guigay, Joel, additional, and Busson, Pierre, additional
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.